Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy

Journal of Clinical Oncology

Volumn 27, Issue 22, 2009, Pages 3650-3658

  Grimwade, David ^a   Jovanovic, Jelena V ^a   Hills, Robert K ^a   Nugent, Elizabeth A ^a   Patel, Yashma ^a   Flora, Rajinder ^a   Diverio, Daniela ^a   Jones, Katy ^a   Aslett, Hannah ^a   Batson, Elaine ^a   Rennie, Kristian ^a   Angell, Roger ^a   Clark, Richard E ^a   Solomon, Ellen ^a   Lo Coco, Francesco ^a   Wheatley, Keith ^a   Burnett, Alan K ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; ANTHRACYCLINE; ARSENIC TRIOXIDE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GEMTUZUMAB OZOGAMICIN; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; RETINOIC ACID; ONCOPROTEIN; ORGANOARSENIC DERIVATIVE; OXIDE;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD SAMPLING; BONE MARROW BIOPSY; CANCER RELAPSE; CLINICAL ASSESSMENT; CONTROLLED STUDY; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; GENE AMPLIFICATION; GENE FUSION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; PATIENT MONITORING; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK FACTOR; TREATMENT RESPONSE; AGED; BLOOD ANALYSIS; BONE MARROW; COHORT ANALYSIS; CONFIDENCE INTERVAL; GENE EXPRESSION REGULATION; GENETICS; HOSPITALIZATION; METABOLISM; METHODOLOGY; MIDDLE AGED; MONITORING; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PREDICTION AND FORECASTING; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ARSENICALS; BLOOD CHEMICAL ANALYSIS; BONE MARROW; COHORT STUDIES; CONFIDENCE INTERVALS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; ONCOGENE PROTEINS, FUSION; OXIDES; PREDICTIVE VALUE OF TESTS; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TRETINOIN;

EID: 68949137224     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.20.1533     Document Type: Article

References (43)

1. Fenaux P, Wang ZZ, Degos L: Treatment of acute promyelocytic leukemia by retinoids. Curr Top Microbiol Immunol 313:101-128, 2007
2. Lo-Coco F, Ammatuna E: Front line clinical trials and minimal residual disease monitoring in acute promyelocytic leukemia. Curr Top Microbiol Immunol 313:145-156, 2007
3. Lo Coco F, Diverio D, Avvisati G, et al: Therapy of molecular relapse in acute promyelocytic leukemia. Blood 94:2225-2229, 1999
4. Esteve J, Escoda L, Martín G, et al: Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans-retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): Benefit of an early intervention. Leukemia 21:446-452, 2007
5. van Dongen JJM, Macintyre EA, Gabert JA, et al: Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Leukemia 13:1901-1928, 1999
6. Heid CA, Stevens J, Livak KJ, et al: Real time quantitative PCR. Genome Res 6:986-994, 1996
7. Marcucci G, Livak KJ, Bi W, et al: Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay. Leukemia 12: 1482-1489, 1998
8. Cassinat B, Zassadowski F, Balitrand N, et al: Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR. Leukemia 14:324-328, 2000
9. Gallagher RE, Yeap BY, Bi W, et al: Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: Assessment of prognostic significance in adult patients from Intergroup protocol 0129. Blood 101:2521-2528, 2003
10. Schnittger S, Weisser M, Schoch C, et al: New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFB-MYH11+ acute myeloid leukemia based on quantification of fusion transcripts. Blood 102:2746-2755, 2003
11. Santamaría C, Chillón MC, Fernández C, et al: Using quantification of the PML-RARα transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia. Haematologica 92:315-322, 2007
12. Gabert J, Beillard E, van der Velden VHJ, et al: Standardization and quality control studies of real-time quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia: A Europe Against Cancer Program. Leukemia 17:2318-2357, 2003
13. Yin JA, Grimwade D: Minimal residual disease evaluation in acute myeloid leukaemia. Lancet 360: 160-162, 2002
14. van der Velden VHJ, Hochhaus A, Cazzaniga G, et al: Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: Principles, approaches, and laboratory aspects. Leukemia 17:1013-1034, 2003
15. Freeman SD, Jovanovic JV, Grimwade D: Development of minimal residual disease directed therapy in acute myeloid leukemia. Semin Oncol 35:388-400, 2008
16. Grimwade D, Diverio D, Harrison G, et al: Detection of minimal residual disease (MRD) in APL by real-time RT-PCR: Analysis of cases entered into the UK MRC ATRA trial. Blood 94:625a, 1999 (suppl 1; abstr)
17. Burnett AK, Hills RK, Grimwade D, et al: Idarubicin and ATRA is as effective as MRC chemotherapy in patients with acute promyelocytic leukaemia with lower toxicity and resource usage: Preliminary results of the MRC AML15 trial. Blood 110:181a, 2007 (abstr)
18. Burnett AK, Grimwade D, Solomon E, et al: Presenting white cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans-retinoic acid: Results of the randomized MRC trial. Blood 93: 4131-4143, 1999
19. Sanz MA, Martín G, González M, et al: Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: A multicenter study by the PETHEMA group. Blood 103:1237-1243, 2004
20. Vey N, Bosly A, Guerci A, et al: Arsenic trioxide in patients with myelodysplastic syndromes: A phase II multicenter study. J Clin Oncol 24:2465-2471, 2006
21. Soignet SL, Frankel SR, Douer D, et al: United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 19:3852-3860, 2001
22. Jovanovic JV, Score J, Waghorn K, et al: Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA positive chronic eosinophilic leukemia. Blood 109: 4635-4640, 2007
23. Cheson BD, Bennett JM, Kopecky KJ, et al: Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21:4642-4649, 2003
24. Szczepański T, Orfão A, van der Velden VH, et al: Minimal residual disease in leukaemia patients. Lancet Oncol 2:409-417, 2001
25. Mortuza FY, Papaioannou M, Moreira IM, et al: Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. J Clin Oncol 20:1094-1104, 2002
26. Cazzaniga G, Biondi A: Molecular monitoring of childhood acute lymphoblastic leukemia using antigen receptor gene rearrangements and quantitative polymerase chain reaction technology. Haematologica 90:382-390, 2005
27. Brüggemann M, Raff T, Flohr T, et al: Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 107:1116-1123, 2006
28. Borowitz MJ, Devidas M, Hunger SP, et al: Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: A Children's Oncology Group study. Blood 111:5477-5485, 2008
29. Stanulla M, Cario G, Meissner B, et al: Integrating molecular information into treatment of childhood acute lymphoblastic leukemia: A perspective from the BFM Study Group. Blood Cells Mol Dis 39:160-163, 2007
30. Sanz MA, Grimwade D, Tallman MS, et al: Management of acute promyelocytic leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 113:1875-1891, 2009
31. Grimwade D: The significance of minimal residual disease in patients with t(15;17). Best Pract Res Clin Haematol 15:137-158, 2002
32. Sanz MA, Tallman MS, Lo-Coco F: Tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia. Blood 105:3019-3025, 2005
33. Falanga A, Rickles FR: Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia. Best Pract Res Clin Haematol 16:463-482, 2003
34. Camacho LH, Soignet SL, Chanel S, et al: Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. J Clin Oncol 18:2620-2625, 2000
35. 3) on event-free survival (EFS) and overall survival (OS) among patients with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup Protocol C9710. J Clin Oncol 25:1s, 2007 (suppl; abstr 2)
36. Tallman MS, Rowe JM: Long-term follow-up and potential for cure in acute promyelocytic leukaemia. Best Pract Res Clin Haematol 16:535-543, 2003
37. Estey EH, Giles FJ, Kantarjian H, et al: Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Blood 94:2230-2235, 1999
38. 3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A 101:5328-5335, 2004
39. Mathews V, George B, Lakshmi KM, et al: Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: Durable remissions with minimal toxicity. Blood 107: 2627-2632, 2006
40. Estey E, Garcia-Manero G, Ferrajoli A, et al: Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 107:3469-3473, 2006
41. Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, et al: Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol 17:131-134, 2006
42. Hughes TP, Kaeda J, Branford S, et al: Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349:1423-1432, 2003
43. Hughes T, Deininger M, Hochhaus A, et al: Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108:28-37, 2006